Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT02252887

Completed

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Metastatic HER2-Positive Breast Cancer
NCT04313075

No longer available

A Compassionate Use Study of Leronlimab in Breast Cancer

Metastatic Triple-Negative Breast Carcinoma
NCT06859593

Completed

Upper Extremity Exercise Capacity Of Breast Cancer

Breast Cancer Survivor | Healty Controls
NCT04720729

Terminated

Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer (MONDRIAN)

HER2-negative Metastatic Breast Cancer
NCT06986213

Enrolling by invitation

Heart Pillow - Chemoteraphy (Hepi_Qt)

Breast Cancer Patients | Rehabilitation Program
NCT04509596

Completed

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Breast Cancer Metastatic
NCT01839838

Completed

APBI Proton Feasibility and Phase II Study

Stage IA-IIA Breast Cancer
NCT04727632

Terminated

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

Estrogen Receptor Positive Breast Cancer
NCT06305702

Completed

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer
NCT03989037

Completed

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

HER2-positive Early Breast Cancer
NCT05932667

Terminated

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer (DEMETER)

Advanced or Metastatic Breast Cancer
NCT05218876

Completed

Effects of Moderate and High-intensity Exercise During Chemotherapy on Muscle Cells in Women With Breast Cancer (PhysCan)

Breast Cancer Female
NCT01698918

Completed

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (BOLERO-4)

Hormone Receptor Positive Breast Cancer
NCT05412459

Completed

99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

Female | HER2-positive Breast Cancer
NCT04316169

Withdrawn

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Advanced Breast Cancer | Solid Tumor
NCT03012477

Completed

CISPLATIN + AZD-1775 In Breast Cancer

Triple-negative Metastatic Breast Cancer
NCT04320693

Approved for marketing

Expanded Access for IMMU-132

Metastatic Triple-Negative Breast Carcinoma
NCT04336917

Completed

Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries

Breast Cancer Surgery | Postoperative Analgesia
NCT03027063

Completed

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

Breast Cancer Female | Adriamycin Toxicity
NCT03080805

Unknown

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

HER2 Positive Metastatic Breast Cancer
NCT02025192

Completed

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

HER2 Positive Metastatic Breast Cancers
NCT03004534

Completed

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Breast Cancer Female
NCT03769428

Completed

Postoperative Analgesia in Breast Cancer Surgery: Safety and Efficiency of Ultrasound Guided Erector Spinae Plane Block (erectspinae)

Breast Cancer Surgery | Postoperative Analgesia
NCT04185649

Unknown

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
NCT02248090

Completed

AZD9496 First Time in Patients Ascending Dose Study

ER+ HER2- Advanced Breast Cancer
NCT00928330

Completed

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Metastatic Breast Cancer
NCT00951665

Completed

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer
NCT01069796

Terminated

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Triple Negative Metastatic Breast Cancer
NCT01502592

Completed

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Breast Cancer | Invasive Adenocarcinoma of the Breast
NCT01635465

Unknown

Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer

Anthracycline-pretreated Metastatic Breast Cancer
NCT01240681

Completed

Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy (IMPACT)

Locally Advanced Breast Cancer (LABC)
NCT02225652

Completed

A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.

Women With Primary Breast Cancer
NCT01594177

Completed

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy (DAFNE)

Unilateral HER2 Positive Breast Cancer
NCT00509769

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Metastatic Breast Cancer
NCT01428414

Unknown

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

HER-2 Positive Breast Cancer
NCT07443943

Recruiting

A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial (AIMSS-RPS)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Localized Breast Carcinoma
NCT01275677

Completed

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Progesterone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7
NCT07599098

Not yet recruiting

Effects of a Pilates Studio Program on Quality of Life and Functional Capacity of Women Undergoing Breast Cancer Treatment (Cancer)

Breast Cancer | Breasts - Female | Breast Cancer in Women
NCT07494448

Not yet recruiting

Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (JAZMINE)

Breast Cancer | HER 2 Positive Advanced Breast Cancer
NCT07443579

Recruiting

Optimal Mammography View Sequencing in Women With a History of Breast Cancer Undergoing Surveillance Mammography (MammoView)

Breast Cancer | Breast Cancer Recurrence | Post Treatment Surveillance
NCT07336771

Not yet recruiting

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer (LABC)
NCT07332975

Recruiting

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

Triple Negative Breast Cancer
NCT07313306

Recruiting

Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise

Breast Cancer | Metastatic Breast Cancer
NCT07283692

Recruiting

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Triple Negative Breast Cancer
NCT07019272

Not yet recruiting

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

HER2-positive Breast Cancer
NCT06973525

Not yet recruiting

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. (HER2-DM-NACT)

HER2-positive Breast Cancer
NCT06786949

Recruiting

Night-shift Work and Breast Cancer (BC-NSW-02/2023)

Breast Cancer Risk Factors
NCT06860529

Recruiting

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer
NCT06739655

Recruiting

Preoperative Radiation Therapy and Immediate Breast Reconstruction (PRADAIIBE)

Cancer | Breast Neoplasms | Breast Carcinoma | Neoplasm | Breast Adenocarcinoma
NCT06731140

Recruiting

Reverse HER2-negative Immune Resistant Breast Cancer (Resilire)

HER2 Negative Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations